Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 5,225 matching trials from the live ClinicalTrials.gov search.
Conditions
Carcinoma, Non-small Cell Lung
Interventions
Abemaciclib, Pemetrexed, Gemcitabine, Ramucirumab, LY3023414, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
Fayetteville, Arkansas • Los Angeles, California • Sacramento, California + 5 more
Conditions
Lung Carcinoma
Interventions
Educational Intervention, Interview, Questionnaire Administration
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Osimertinib, Positron Emission Tomography, Telaglenastat Hydrochloride, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Coral Gables, Florida • Deerfield Beach, Florida + 8 more
Terminated Phase 2Phase 3 Interventional Results available

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

NCT01761747
Conditions
Non-Small Cell Lung Cancer, Head and Neck Cancer
Interventions
ponatinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Boston, Massachusetts
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
Conditions
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
Interventions
MYTX-011
Drug
Lead sponsor
Mythic Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 13 more
Completed Not applicable Interventional

Lung Screening Study

NCT00006382
Conditions
Lung Cancer
Interventions
bronchoscopic and lung imaging studies, comparison of screening methods, computed tomography, radiography, study of high risk factors
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
55 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
6
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Detroit, Michigan + 3 more
Conditions
Lung Cancer
Interventions
Text Messages (TM+), Chat bot (CA), Video, Reactive Patient Navigation (RPN), Proactive Patient Navigation (PPN)
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
50 Years to 80 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Not applicable Interventional Results available

Personal Resilience Empowerment Program Study

NCT03644173
Conditions
Lung Cancer, Cholangiocarcinoma, Pancreatic Cancer, Liver Cancer
Interventions
Personal Resilience Empowerment Program including 5 sessions with health coaches
Behavioral
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Neptune City, New Jersey • Red Bank, New Jersey
Conditions
Small Cell Lung Cancer
Interventions
Topotecan and Pasireotide
Drug
Lead sponsor
South Florida Veterans Affairs Foundation for Research and Education
Federal
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Miami, Florida
Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
Amrubicin, Carboplatin, Pegfilgrastim
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
20
States / cities
Jonesboro, Arkansas • Fort Myers, Florida • Lakeland, Florida + 15 more
Conditions
Non-small Cell Lung Cancer
Interventions
communication intervention, Real Time Registry and data feedback only
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Terminated Phase 2 Interventional Results available

Pembro+Chemo in Brain Mets

NCT04964960
Conditions
Lung Cancer, Lung Cancer Metastatic, Brain Cancer, Cancer
Interventions
Pembrolizumab, Nab paclitaxel, Paclitaxel, Pemetrexed, Carboplatin
Drug
Lead sponsor
John L. Villano, MD, PhD
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
imatinib mesylate, paclitaxel
Drug
Lead sponsor
University of Washington
Other
Eligibility
70 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Albuquerque, New Mexico • Seattle, Washington
Conditions
Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinoma
Interventions
Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer

NCT05144542
Conditions
Lung Carcinoma
Interventions
Nicotine Replacement
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
50 Years to 80 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lung Cancer
Interventions
batabulin sodium
Drug
Lead sponsor
Tularik
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
San Francisco, California • Nashville, Tennessee
Conditions
Non-small Cell Lung Cancer
Interventions
MGY825
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 1 more
Conditions
Lung Cancer
Interventions
AmDTx-PCSP, AmDTx-2048, Questionnaires
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer
Interventions
PLX3397, Pembrolizumab
Drug · Biological
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 7 more
Conditions
Non-Small Cell Lung Cancer
Interventions
CBT-1, Placebo
Drug · Other
Lead sponsor
CBA Research
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Tuscon, Arizona
Conditions
Lung Cancer
Interventions
Ad5CMV-p53 gene
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
3
States / cities
Nashville, Tennessee • Green Bay, Wisconsin
Conditions
Small Cell Lung Carcinoma
Interventions
coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830, coformulation favezelimab/pembrolizumab, R-DXd
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
12
States / cities
Gilbert, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 7 more
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck Cancer, Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
ALX2004
Drug
Lead sponsor
ALX Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
La Jolla, California • Santa Monica, California • Tampa, Florida + 9 more